



FOR IMMEDIATE RELEASE

Dr. Scott Segal Examines Nonstimulant Treatment for ADHD Pediatric Patients

Miami, Florida. February 6, 2011-- Dr. Scott Segal, MD, President and Director of Clinical Operations at Segal Institute for Clinical Research, was recently recognized by the Journal of the Academy of Child and Adolescent Psychiatry for his role in examining the efficacy of a Clonidine Extended-Release Tablets for pediatric patients with Attention-Deficit/Hyperactivity Disorder (ADHD).

"Typical treatment guidelines for ADHD recommend stimulants, but nearly 15% of patients can be unresponsive or have adverse reactions such as decreased appetite from stimulant treatments," explains Dr. Segal. "It's clear that a significant percentage of patients are in need of a nonstimulant therapy option that quells ADHD symptoms without causing side effects such as extensive drowsiness."

The need to find the equilibrium in ADHD therapy options is precisely for the reason for the Clonidine Extended-Release (CLON-XR) phase IV study for pediatric patients, in which Dr. Segal acted as a principal investigator. Dr. Segal's extensive experience as a principal investigator with approximately 300 multi-centered, phase I-IV clinical studies offered the knowledge and skill necessary to implement the eight week study.

"We not only examined the efficacy, but also the safety of this treatment option. For children and adolescents with ADHD, a therapy option that treats but doesn't create serious sedation adverse effects is an obvious preference for patients and parents," says Dr. Segal.

While there are many studies that have examined the efficacy of ADHD therapy treatments, few studies have examined the nonstimulant, extended release capabilities of a sedative tablet in pediatric patients. The study was conducted at 13 centers in the U.S between October 2007 and August 2008, with a total of 230 participating patients.

The results were reported by the Journal of the American Academy of Child and Adolescent Psychiatry in February of 2011, explaining that the Clonidine extended release tablets were generally well tolerated, with most adverse effects being mild to moderate.

"A small percentage of patients did experience mild to moderate adverse effects, however for a study designed to give the same dosage to each patient no matter age or weight, these results are promising," said Dr. Segal.

Dr. Segal is Board-Certified in Adult Psychiatry and Board-Certified in Child and Adolescent Psychiatry. To date, Dr. Segal has participated in 18 ADHD focused clinical trial studies.

Segal Institute for Clinical Research is a consortium of research sites specializing in psychiatric, neurological, addiction, medical and women's health clinical trials. A 60-plus staff of full-time Principal Investigators, Sub-investigators, coordinators, research assistants and Master's- and Doctorate-level raters conducts clinical trials in outpatient, inpatient, nursing homes, and sleep laboratories. Founded in 1998, Segal Institute for Clinical Research was created as a division of Compass Health Systems, a multi-specialty group practice.